Clinical Trial

Hybrid Endoscopic Hemithyroidectomy and Targeted Ablation for Bilateral Papillary Thyroid Carcinoma

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 3, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study evaluates a thyroid-function-preserving alternative to routine total thyroidectomy for bilateral papillary thyroid carcinoma (PTC). Eligible adults undergo remote-access gas-less axillo-breast endoscopic hemithyroidectomy with level VI dissection on the dominant side, followed by ultrasound-guided radiofrequency ablation (RFA) of a ≤7 mm contralateral focus during the same anesthesia. Outcomes include structural-recurrence-free survival, endocrine-function preservation, safety, and quality of life over 24 months.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-13.
Trial Details
NCT Number NCT07033572
Lead Sponsor Fujian Medical University
Conditions Thyroid Neoplasms, Carcinoma, Papillary
Enrollment 60 participants
Start Date 2018-06-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-03